Emmie N Upners1,2, Anders Juul1,2. 1. Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 2. International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: Reduction of adult height by sex steroid treatment was introduced decades ago in tall statured children, but controlled trials are lacking and treatment is controversial. In this study, we wanted to evaluate the phenotypic characteristics in girls referred due to tall stature and the effect of oral administration of 17β-estradiol on predicted adult height in girls. METHODS: A single-centre retrospective observational study of 304 girls evaluated consecutively due to tall stature between 1993 and 2013. 207 patients diagnosed with constitutionally tall stature (CTS), 60 (29%) girls ended up being treated with 17β-estradiol with a duration of 1.7 y (1.2; 2.5) (median (25; 75 percentile)), and final height was available in 26 girls. RESULTS: At baseline, 20% of girls with CTS had supranormal IGF-I, whereas reproductive hormones were within the normal range. Final adult height was reduced with 1.6 ± 2.1 cm in the girls treated with 17β-estradiol when compared to initial prediction. Chronological age, bone age, estradiol, and IGF-I at baseline or estrogen dose did not predict height reduction. CONCLUSIONS: Serum IGF-I was elevated tall statured children, but did not predict the effect of treatment with 17β-estradiol, which caused a modest reduction in final adult height.
BACKGROUND: Reduction of adult height by sex steroid treatment was introduced decades ago in tall statured children, but controlled trials are lacking and treatment is controversial. In this study, we wanted to evaluate the phenotypic characteristics in girls referred due to tall stature and the effect of oral administration of 17β-estradiol on predicted adult height in girls. METHODS: A single-centre retrospective observational study of 304 girls evaluated consecutively due to tall stature between 1993 and 2013. 207 patients diagnosed with constitutionally tall stature (CTS), 60 (29%) girls ended up being treated with 17β-estradiol with a duration of 1.7 y (1.2; 2.5) (median (25; 75 percentile)), and final height was available in 26 girls. RESULTS: At baseline, 20% of girls with CTS had supranormal IGF-I, whereas reproductive hormones were within the normal range. Final adult height was reduced with 1.6 ± 2.1 cm in the girls treated with 17β-estradiol when compared to initial prediction. Chronological age, bone age, estradiol, and IGF-I at baseline or estrogen dose did not predict height reduction. CONCLUSIONS: Serum IGF-I was elevated tall statured children, but did not predict the effect of treatment with 17β-estradiol, which caused a modest reduction in final adult height.
Authors: Emelie Benyi; Helle Kieler; Marie Linder; Martin Ritzén; Jan Carlstedt-Duke; Torsten Tuvemo; Otto Westphal; Lars Sävendahl Journal: Horm Res Paediatr Date: 2014-06-11 Impact factor: 2.852
Authors: Hans Henrik Thodberg; Oskar G Jenni; Jon Caflisch; Michael B Ranke; David D Martin Journal: J Clin Endocrinol Metab Date: 2009-11-19 Impact factor: 5.958
Authors: A Juul; P Bang; N T Hertel; K Main; P Dalgaard; K Jørgensen; J Müller; K Hall; N E Skakkebaek Journal: J Clin Endocrinol Metab Date: 1994-03 Impact factor: 5.958
Authors: Emelie Benyi; Maria Berner; Inger Bjernekull; Anders Boman; Dionisios Chrysis; Ola Nilsson; Anne Waehre; Henrik Wehtje; Lars Sävendahl Journal: Int J Pediatr Endocrinol Date: 2010-12-02